Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Telios Pharma, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT06686472
- Locations
- 🇺🇸
Telios Investigative Site, Memphis, Tennessee, United States
A Study Of TL-925 For The Treatment of AC
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Telios Pharma, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06293820
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Telios Pharma, Inc.
- Target Recruit Count
- 880
- Registration Number
- NCT06225973
- Locations
- 🇺🇸
Wyse Eyecare, Northbrook, Illinois, United States
🇺🇸Nvision - Torrance, Torrance, California, United States
🇺🇸Andover Eye Associates - Andover, Andover, Massachusetts, United States
A Study of TL-925 for the Treatment of Allergic Conjunctivitis
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Telios Pharma, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT06153342
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
A Study of TL-925 as a Treatment for Dry Eye Disease
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Telios Pharma, Inc.
- Target Recruit Count
- 107
- Registration Number
- NCT05745064
- Locations
- 🇺🇸
Vision Institute, Colorado Springs, Colorado, United States
🇺🇸Andover Eye Associates, Andover, Massachusetts, United States
🇺🇸Aesthetic Eye Care, Newport Beach, California, United States
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
- Conditions
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Telios Pharma, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05280509
- Locations
- 🇮🇹
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy
🇮🇹Azienda Ospedaliera di Perugia-Ospedale S. Maria della Misericordia, Perugia, Italy
🇪🇸Hospital Quironsalud de Zaragoza, Zaragoza, Spain
TL-895 and KRT-232 Study in Acute Myeloid Leukemia
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Telios Pharma, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04669067
- Locations
- 🇦🇹
Medical University Vienna, Department of Internal Medicine I, Clinical Department of Hematology and Hemostaseology, Vienna, Austria
🇺🇸Rush University Medical Center, Division of Hematology Oncology and Cell Therapy, Chicago, Illinois, United States
🇫🇷Claude Huriez Hospital, Lille, France
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- Conditions
- Interventions
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Telios Pharma, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT04655118
- Locations
- 🇦🇺
Border Medical Oncology, East Albury, Australia
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
🇵🇱Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Klinika Hematologi, Bydgoszcz, Poland
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Telios Pharma, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04419623
- Locations
- 🇺🇸
Georgia Cancer Center, Augusta, Georgia, United States
🇺🇸The Ohio State Comprehensive Cancer Center, Columbus, Ohio, United States
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Telios Pharma, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT02825836
- Locations
- 🇺🇸
Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇵🇱Pratia MCM Krakow, Krakow, Poland
🇵🇱Szpital Wojewódzki, Opole, Poland